HR+
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Summary: Efficacy of Sacituzumab Govitecan in HR+/HER2- mBC and mTNBC - Clinical Data and Implications
FEATURING
Simone Nardin
- 5 views
- January 8, 2025
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: PATINA Trial - Palbociclib Combined With Endocrine and HER2-Targeted Therapy in ER+/HER2+ mBC
FEATURING
Komal Jhaveri
- 3 views
- January 8, 2025
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: EMBER-3 Trial - Imlunestrant Monotherapy and Combined With Abemaciclib in ER+/HER2- aBC
FEATURING
Komal Jhaveri
- 121 views
- January 8, 2025
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Impact of Ribociclib Dose Reduction on Efficacy in HR+/HER2− eBC: Insights From the NATALEE Trial
FEATURING
Erika Hamilton
- 43 views
- January 7, 2025
- 1
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Neoadjuvant Niraparib and Dostarlimab in BRCA-Mutated HR+/HER2- eBC - Results From TBCRC 056
FEATURING
Erica Mayer
- 15 views
- January 5, 2025
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: EUROPA Trial - HRQoL With Radiotherapy vs. Endocrine Therapy in Luminal-Like eBC in Women Aged 70+
FEATURING
Icro Meattini
- 20 views
- January 5, 2025
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- eBC
FEATURING
Nan Chen
- 55 views
- January 2, 2025
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Association of HER2-Low Status With Progression-Free Survival in HR+/HER2- aBC Following CDK 4/6 Inhibitor Failure
FEATURING
José Antonio García Gordillo
- 125 views
- December 24, 2024
- 2
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Progesterone Receptor Expression and Recurrence Scores in HR+/HER2- eBC Regardless of Menopausal Status
FEATURING
Federica Martorana
- 31 views
- December 24, 2024
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: DESTINY-Breast06 - Monday Morning Practice
FEATURING
Sara Tolaney,
Hope Rugo
- 575 views
- December 22, 2024
- 3
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: PATINA - Monday Morning Practice
FEATURING
Sara Tolaney,
Hope Rugo
- 339 views
- December 22, 2024
- 8
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: PADMA - Monday Morning Practice
FEATURING
Sara Tolaney,
Hope Rugo
- 236 views
- December 22, 2024
- 5
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Nab-Paclitaxel vs. Solvent-Based Paclitaxel in High-Risk eBC - Final Survival Results of WSG ADAPT HR+/HER2- Trial
FEATURING
Sherko Kuemmel
- 146 views
- December 20, 2024
- 3
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Impact of Oncotype DX Risk Stratification on Chemotherapy Use and Survival Outcomes in HR+ Node- eBC
FEATURING
Kai Johnson
- 132 views
- December 20, 2024
- 2
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Prediction of Chemotherapy Benefit by MammaPrint® in HR+/HER2- eBC - FLEX Registry Data
FEATURING
Adam Brufsky
- 64 views
- December 20, 2024
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: MammaPrint® and Predictive Pathways of CDK4/6 Inhibitor Resistance in ER+/HER2- eBC
FEATURING
Adam Brufsky
- 54 views
- December 20, 2024
- 1
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: Impact of Prior Treatment, ESR1 Mutations, and PI3K Pathway on Elacestrant Outcomes in HR+/HER2- Advanced Breast Cancer
FEATURING
Maxwell Lloyd
- 57 views
- December 17, 2024
- 2